Metastatic squamous non-small-cell lung cancer (NSCLC) is an aggressive form of lung cancer with poor survival outcomes. First-line treatment is limited to chemotherapy or immune checkpoint inhibitor-based therapy such as Keytruda (Merck & Co.), Opdivo plus Yervoy (Bristol Myers Squibb), Tecentriq (Roche), and Libtayo (Sanofi / Regeneron). Targeted therapies such as the EGFR inhibitor Gilotrif / Giotrif (Boehringer Ingelheim) are available for some patients in subsequent lines, but not all patients respond to treatment. The lack of biomarker-driven therapies leaves patients with metastatic squamous NSCLC with fewer treatment options compared with other NSCLC patient populations. Thus, a strong need remains for more-effective treatments for this patient population.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in June 2021.
Key companies: Merck & Co., Bristol Myers Squibb, Roche / Genentech, Sanofi / Regeneron, Boehringer Ingelheim.
Key drugs: Keytruda, Opdivo + Yervoy, Tecentriq, Libtayo, Gilotrif / Giotrif, Abraxane.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by our experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator